# INST Phase II Trial of Gemcitabine and Irinotecan in Patients With Relapsed or Refractory Lymphoma.

> **NCT00276003** · PHASE2 · COMPLETED · sponsor: **University of New Mexico** · enrollment: 22 (actual)

## Conditions studied

- Non-Hodgkin's Lymphoma
- Cancer

## Interventions

- **DRUG:** Gemcitabine, Irinotecan, Allopurinol.

## Key facts

- **NCT ID:** NCT00276003
- **Lead sponsor:** University of New Mexico
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-08
- **Primary completion:** 2005-06
- **Final completion:** 2005-08
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2010-01-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00276003

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00276003, "INST Phase II Trial of Gemcitabine and Irinotecan in Patients With Relapsed or Refractory Lymphoma.". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00276003. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*